170 related articles for article (PubMed ID: 8313368)
41. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
42. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
43. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states.
Kruithof EK; Gudinchet A; Bachmann F
Thromb Haemost; 1988 Feb; 59(1):7-12. PubMed ID: 3129809
[TBL] [Abstract][Full Text] [Related]
44. Increased basal levels of free plasminogen activator activity found in human aqueous humor.
Wang Y; Taylor DM; Smalley DM; Cone RE; O'Rourke J
Invest Ophthalmol Vis Sci; 1994 Aug; 35(9):3561-6. PubMed ID: 8056534
[TBL] [Abstract][Full Text] [Related]
45. Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer.
Plas E; Carroll VA; Jilch R; Simak R; Mihaly J; Melchior S; Thüroff JW; Binder BR; Pflüger H
Cytometry; 2001 Jun; 46(3):184-9. PubMed ID: 11449410
[TBL] [Abstract][Full Text] [Related]
46. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
Darras V; Thienpont M; Stump DC; Collen D
Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
[TBL] [Abstract][Full Text] [Related]
47. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
48. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y; Suzumiya J; Marutsuka K; Sumiyoshi A; Hashida S; Ishikawa E
Cancer Res; 1989 Feb; 49(4):1067-70. PubMed ID: 2492205
[TBL] [Abstract][Full Text] [Related]
49. Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors.
Häkel C; Ueda Y; Tsuchya H; Herrera A; Blasius S; Roessner A
Zentralbl Pathol; 1994 Nov; 140(4-5):363-9. PubMed ID: 7826985
[TBL] [Abstract][Full Text] [Related]
50. [Plasminogen activator inhibitors from neoplastic tissues].
Mirowski M; Wierzbicki R
Postepy Hig Med Dosw; 1991; 45(1-2):119-27. PubMed ID: 1923993
[TBL] [Abstract][Full Text] [Related]
51. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR
Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631
[TBL] [Abstract][Full Text] [Related]
52. Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.
Sałuda-Gorgul A; Pytel J; Olborski B; Greger J
Z Naturforsch C J Biosci; 2002; 57(3-4):366-71. PubMed ID: 12064742
[TBL] [Abstract][Full Text] [Related]
53. The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines.
Ishikawa H; Satoh H; Kamma H; Naito T; Ohtsuka M; Ogata T; Hasegawa S
J Exp Ther Oncol; 1996 Nov; 1(6):390-6. PubMed ID: 9414430
[TBL] [Abstract][Full Text] [Related]
54. Increased expression of urokinase type plasminogen activator(u-PA), plasminogen activator inhibitor-1(PAI-1), and collagenases in Caco-2 cells infected by Salmonella typhimurium.
Park CG; Goh YJ; Kook SH; Park HK; Kim BJ; Cha CY; Kook YH
J Korean Med Sci; 1997 Feb; 12(1):23-31. PubMed ID: 9142656
[TBL] [Abstract][Full Text] [Related]
55. [A plasminogen regulation system in brain tumors].
Kit OI; Frantsiyants EM; Kozlova LS; Rostorguev EE; Balyazin-Parfenov IV; Pogorelova YA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(2):22-27. PubMed ID: 28524122
[TBL] [Abstract][Full Text] [Related]
56. The plasminogen-activation system in ovarian tumors.
Pujade-Lauraine E; Lu H; Mirshahi S; Soria J; Soria C; Bernadou A; Kruithof EK; Lijnen HR; Burtin P
Int J Cancer; 1993 Aug; 55(1):27-31. PubMed ID: 8344749
[TBL] [Abstract][Full Text] [Related]
57. Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells.
Wojta J; Nakamura T; Fabry A; Hufnagl P; Beckmann R; McGrath K; Binder BR
Blood; 1994 Jul; 84(1):151-7. PubMed ID: 7517205
[TBL] [Abstract][Full Text] [Related]
58. Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis.
Sawaya R; Yamamoto M; Rämö OJ; Shi ML; Rayford A; Rao JS
Neurosurgery; 1995 Feb; 36(2):375-80; discussion 380-1. PubMed ID: 7731519
[TBL] [Abstract][Full Text] [Related]
59. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Sier CF; Verspaget HW; Griffioen G; Verheijen JH; Quax PH; Dooijewaard G; De Bruin PA; Lamers CB
Gastroenterology; 1991 Dec; 101(6):1522-8. PubMed ID: 1955118
[TBL] [Abstract][Full Text] [Related]
60. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M
Hamostaseologie; 2005 Aug; 25(3):301-10. PubMed ID: 16113755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
